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Introduction {#sec1}
============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single-stranded, enveloped RNA virus that was first isolated in Wuhan, China in December, 2019 from a cluster of acute respiratory illness cases ([@bib21]). SARS-CoV-2 is the etiologic agent of coronavirus disease 2019 (COVID-19), which as of June 17, 2020 has more than 8.2 million confirmed cases causing 445,000 deaths. Virtually all countries and territories have been affected, with major epidemics in Central China, Italy, Spain, France, Iran, Russia, Brazil, India, Peru, the United Kingdom, and the United States. SARS-CoV-2 is thought to be of zoonotic origin and is closely related to the original SARS-CoV ([@bib59]; [@bib60]). Most cases are spread by direct human-to-human transmission, with community transmission occurring from both symptomatic and asymptomatic individuals ([@bib1]). This has resulted in a global pandemic with severe economic, political, and social consequences. The development, characterization, and deployment of an effective vaccine or antibody prophylaxis or treatment against SARS-CoV-2 could prevent morbidity and mortality and curtail its epidemic spread.

The viral spike protein (S) mediates all steps of coronavirus entry into target cells, including receptor binding and membrane fusion ([@bib50]). During viral biogenesis, the S protein undergoes furin-dependent proteolytic processing as it transits through the trans-Golgi network and is cleaved into S1 and S2 subunits that function in receptor binding and membrane fusion, respectively ([@bib53]). Angiotensin-converting enzyme 2 (ACE2) serves as a cell surface receptor ([@bib28]; [@bib56]) for SARS-CoV-2, and productive infection is facilitated by additional processing of S2 by the host cell serine protease TMPRSS2 ([@bib22]).

Laboratory studies of SARS-CoV-2 require biosafety level 3 (BSL3) containment with positive-pressure respirators. Single-round pseudotyped viruses complemented by expression of the SARS-CoV-2 S protein *in trans* serve as biosafety level 2 (BSL2) surrogates that can facilitate studies of viral entry and the inhibition of infection by neutralizing antibodies and other inhibitors ([@bib22]; [@bib27]; [@bib38]; [@bib39]). Such pseudotyping approaches are used routinely by many laboratories for other highly pathogenic coronaviruses, including SARS-CoV and MERS-CoV ([@bib15], [@bib16]; [@bib20]; [@bib25]). Viral pseudotyping assays are limited by the need to express the glycoprotein *in trans* and preclude forward genetic studies of the viral envelope protein. Expression of the glycoprotein is often accomplished by plasmid transfection, which requires optimization to minimize batch variation. Assays performed with such pseudotyped viruses rely on relative levels of infectivity as measured by a reporter assay without correlation to an infectious titer. It also is unknown how the display of S proteins on a heterologous virus impacts viral entry, antibody recognition, and antibody neutralization compared to infectious coronavirus. This question is important because neutralization assays are used to establish correlates of protection for vaccine and antibody-based countermeasures, and most manufacturers lack access to high-containment laboratories to test antibody responses against highly pathogenic coronaviruses such as SARS-CoV-2.

Here, we developed a simple and robust BSL2 assay for evaluating SARS-CoV-2 entry and its inhibition by antibodies. We engineered an infectious molecular clone of vesicular stomatitis virus (VSV) to encode the SARS-CoV-2 S protein in place of the native envelope glycoprotein (G) and rescued an autonomously replication-competent virus bearing the spike. Through passage of VSV-eGFP-SARS-CoV-2, we selected a gain-of-function mutation in S that allowed more efficient viral propagation yielding titers of \>1 × 10^8^ plaque-forming units (PFU)/mL. We characterized this variant with respect to inhibition by soluble human ACE2-Fc and monoclonal and polyclonal antibodies from humans and compared those results to neutralization tests with a clinical isolate of SARS-CoV-2. These studies demonstrate that a recombinant VSV expressing SARS-CoV-2 S behaves analogously to a clinical isolate of SARS-CoV-2, providing a useful high-throughput BSL2 assay for studying antibody neutralization or inhibition of viral spike-mediated entry.

Results {#sec2}
=======

A Replication-Competent, Infectious VSV Chimera with SARS-CoV-2 S Protein {#sec2.1}
-------------------------------------------------------------------------

To generate a replication-competent virus to study entry and neutralization of SARS-CoV-2 at BSL2, we engineered an infectious molecular clone of VSV by replacing the endogenous glycoprotein (G) with SARS-CoV-2 S ([Figure 1](#fig1){ref-type="fig"} A). SARS-CoV-2 S protein contains an endoplasmic reticulum (ER) retention sequence in the cytoplasmic tail (KxHxx-COOH) because virion assembly occurs in ER-Golgi intermediate compartments ([@bib33]; [@bib34]; [@bib43]). We pre-emptively altered that sequence to AxAxx to facilitate retargeting of S to the plasma membrane, the site of VSV assembly. Using established approaches ([Figure S1](#mmc1){ref-type="supplementary-material"}A) ([@bib55]), we recovered infectious VSV-eGFP-SARS-CoV-2-S~AA~ as determined by expression of the virus-encoded eGFP reporter **(** [Figure 1](#fig1){ref-type="fig"}A, right). However, VSV-eGFP-SARS-CoV-2-S~AA~ propagation was inefficient on Vero CCL81 cells. This result prompted us to test additional modifications of the cytoplasmic tail of S, which were also defective in autonomous amplification ([Figure S1](#mmc1){ref-type="supplementary-material"}B). To overcome this limitation, we used a forward genetic approach to isolate two adaptive variants of VSV-eGFP-SARS-CoV-2-S~AA~ **(** [Figure S1](#mmc1){ref-type="supplementary-material"}C). Virus was plaque-purified from the transfected cell supernatants, and one variant was passaged twice on Vero CCL81 cells. Following subsequent plaque isolation and serial amplification, we sequenced the viral RNA in infected cells at the seventh passage. A second, independent plaque from transfected cell supernatants was passaged an additional five times on a rhesus monkey MA104 cell line. Both approaches led to the emergence of a virus that contained a single mutation, a cysteine to stop mutation at residue 1253 (TGC to TGA at nucleotide 3759), which truncates the cytoplasmic tail of SARS-CoV-2 S by 21 residues ([Figure 1](#fig1){ref-type="fig"}A). This virus, hereafter referred to as VSV-SARS-CoV-2-S~Δ21~, was passed 12 times in total to assess genetic stability by next generation sequencing, which revealed no additional mutations in the spike (SRA: SRR11878607; BioProject: PRJNA635934). Comparison of plaque morphology of VSV-SARS-CoV-2-S~Δ21~ and VSV-eGFP-SARS-CoV-2-S~AA~ on three Vero cell subtypes and MA104 cells demonstrates that the selected variant spreads more efficiently ([Figure 1](#fig1){ref-type="fig"}B). Screening of a larger panel of cell types ([Figure 1](#fig1){ref-type="fig"}C) identified MA104 and Vero E6 cells as supporting the highest levels of virus production. Ectopic expression of TMPRSS2 led to a further ∼10-fold increase in viral titer and larger plaque size ([Figure 1](#fig1){ref-type="fig"}D). VSV-SARS-CoV-2-S~Δ21~ also was capable of infecting Calu-3 cells, a human epithelial lung adenocarcinoma cell line ([Figure S2](#mmc1){ref-type="supplementary-material"}).Figure 1Generation and Characterization of an Infectious VSV-SARS-CoV-2 Chimera(A) A schematic diagram depicting the genomic organization of the VSV recombinants. Shown 3′ to 5′ are the leader region (Le), eGFP, nucleocapsid (N), phosphoprotein (P), matrix (M), glycoprotein (G) or SARS-CoV-2 S, large polymerase (L), and trailer region (Tr). On right, infection of Vero CCL81 cells with supernatant from cells transfected with the eGFP reporter VSV-SARS-CoV-2-S~AA~. Images were acquired 44 h post-infection (hpi) using a fluorescence microscope, and GFP and transmitted light images were merged using ImageJ. Shown at bottom, the alignment of the cytoplasmic tail of the VSV-SARS-CoV-2-S~AA~ and the sequence resulting from forward genetic selection of a mutant, which truncated the cytoplasmic tail by 21 amino acids. Mutations deviating from the wild-type spike are indicated in red, and an asterisk signifies a mutation to a stop codon.(B) Plaque assays were performed to compare the spread of VSV-SARS-CoV-2-S~AA~ rescue supernatant and VSV-SARS-CoV-2-S~Δ21~ on Vero CCL81, Vero E6, Vero-furin, and MA104 cells. Plates were scanned on a biomolecular imager and expression of eGFP is shown 92 hpi (representative images are shown; n \> 3 except for S~AA~ on Vero E6, Vero-furin, and MA104 cells).(C) The indicated cell types were infected with VSV-SARS-CoV-2-S~Δ21~ at an MOI of 0.5. Cells and supernatants were harvested at 24 hpi and titrated on MA104 cells (data are pooled from three or more independent experiments; error bars indicate standard deviation of the mean.(D Top: the indicated cells were infected with VSV-SARS-CoV-2-S~Δ21~ at an MOI of 2. Images were acquired 7.5 hpi using a fluorescence microscope and GFP, and transmitted light images were processed and merged using ImageJ (data are representative of two independent experiments). Bottom: Plaque assays were performed on the indicated cell types using VSV-SARS-CoV-2-S~Δ21~. Images showing GFP expression were acquired 48 hpi using a biomolecular imager (data are representative of at least three independent experiments; standard deviations of the mean are shown).(E) Western blotting was performed on concentrated VSV-SARS-CoV-2-S~Δ21~ and wild-type VSV particles on an 8% non-reducing SDS-PAGE gel. S1 was detected using a cross-reactive anti-SARS-CoV mAb (CR3022) (data are representative of two independent experiments).(F) BSRT7/5 cells were inoculated at an MOI of 10 with VSV-eGFP, G-complemented VSV-SARS-CoV-2-S~Δ21~, or mock infected (not shown), and were metabolically labeled with \[^35^S\] methionine and cysteine for 20 h starting at 5 hpi in the presence of actinomycin D. Viral supernatants were analyzed by SDS-PAGE. A representative phosphor-image is shown from two independent experiments. An asterisk indicates a band that also was detected in the mock lane (not shown).(G) Purified VSV-WT and VSV-SARS-CoV-2-S~Δ21~ particles were subjected to negative stain electron microscopy; scale bars are equivalent to 100 nm. Prefusion structures of each respective glycoprotein are modeled above each EM image (PDB: [5I2S](pdb:5I2S){#intref0080} and [6VSB](pdb:6VSB){#intref0085}). See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

SARS-CoV-2-S~**Δ21**~ Is Incorporated into Infectious VSV Particles {#sec2.2}
-------------------------------------------------------------------

To confirm incorporation of SARS-CoV-2 S into particles, we first amplified the virus in the presence of VSV G to allow infection of cell types independently of the S protein. The VSV G *trans*-complemented VSV-SARS-CoV-2-S~Δ21~ efficiently infects HEK293T cells, which then serve as a source of production of virus particles containing SARS-CoV-2 S protein. Western blotting of supernatants with CR3022, a cross-reactive anti-S monoclonal antibody (mAb) ([@bib49]; [@bib57]), established the presence of S~Δ21~ in VSV-SARS-CoV-2-S~Δ21~ particles, but not in the parental VSV ([Figure 1](#fig1){ref-type="fig"}E). The protein detected migrated at ∼100 kilodaltons, a band that corresponds to the cleaved S1 subunit of the glycoprotein ([@bib54]). To examine whether the S~Δ21~ incorporated into VSV particles is processed to S1 and S2, we performed \[^35^S\] cysteine-methionine metabolic labeling in BSRT7 cells, which support robust VSV replication, and analyzed released particles by SDS-PAGE and phosphorimaging. In addition to the VSV structural proteins (N, P, M, and L), two additional bands that correspond in size to glycosylated S1 (107 kDa) and S2~Δ21~ (85 kDa) were observed for VSV-SARS-CoV-2-S~Δ21~ ([Figure 1](#fig1){ref-type="fig"}F). Negative-stain electron microscopy of sucrose-gradient purified virus particles revealed that the membrane protein projecting from VSV-SARS-CoV-2-S~Δ21~ is larger than observed on wild-type VSV particles ([Figure 1](#fig1){ref-type="fig"}G), which reflects the larger size of the coronavirus spike.

A High-Throughput Focus-Forming Assay with a Clinical Isolate of SARS-CoV-2 {#sec2.3}
---------------------------------------------------------------------------

VSV-SARS-CoV-2-S~Δ21~ has several advantages for detection and measuring of neutralizing antibodies, including lower biosafety containment level, ease of production and use, and rapid reporter gene readout. Nonetheless, the difference in virus morphology (spherical CoV versus bullet-shaped VSV) and possible effects on the conformational display of S on the virion surface raise questions of whether the accessibility of epitopes and stoichiometry of antibody neutralization is similar to authentic SARS-CoV-2. A direct comparison with a clinical isolate of SARS-CoV-2 is necessary to establish the utility of VSV-SARS-CoV-2-S~Δ21~ for assays of viral entry and antibody neutralization.

We designed a high-throughput assay for titrating SARS-CoV-2 that could be applied to multiple cell substrates. Instead of using a plaque assay---which relies on the capacity for a virus to cause cell death, which can vary across cell types---we developed a focus-forming assay (FFA) and viral antigen detection as a measure of infectivity. We propagated SARS-CoV-2 in four different producer cell types (Vero CCL81, Vero E6, Vero-furin, and MA104 cells) and then measured the number and size of foci after staining recipient cells with an anti-S mAb. With SARS-CoV-2 stocks generated from each producer cell type, we observed distinct foci across recipient cell substrates at approximately 30 h post-inoculation ([Figure 2](#fig2){ref-type="fig"} A). We consistently observed the highest viral titers and largest foci sizes with Vero-furin and MA104 cells ([Figures 2](#fig2){ref-type="fig"}B and 2C). However, the larger foci were more difficult to enumerate on an automated Immunospot reader and required additional manual quality control analysis. Because of this, we used Vero E6 cells for our rapid focus-reduction neutralization tests (FRNT) in subsequent experiments.Figure 2Development of a SARS-CoV-2 Focus-Forming Assay and a VSV-SARS-CoV-2-S~Δ21~ eGFP-Reduction Assay(A--C) Representative focus forming assay images (A) of viral stocks generated from each producer cell type (top) were developed on the indicated cell substrates (indicated on the left side). Data are representative of two independent experiments. Foci obtained in (A) were counted (B) and the size was determined (C) using an ImmunoSpot plate reader (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 by one-way ANOVA with Tukey's multiple comparisons test; error bars indicate standard error of the mean).(D) Representative serial dilution series of VSV-SARS-CoV-2-S~Δ21~ on Vero E6 cells. The total number of infected cells per well was quantified using an automated microscope. Insets of enhanced magnification are shown in red. Data are representative of two independent experiments.

A High-Throughput, eGFP-Based Neutralization Assay for VSV-SARS-CoV-2-S~Δ21~ {#sec2.4}
----------------------------------------------------------------------------

In parallel, we developed a high-throughput method to measure neutralization of VSV-SARS-CoV-2-S~Δ21~. As VSV-SARS-CoV-2-S~Δ21~ encodes an eGFP reporter and viral gene expression is robust, eGFP-positive cells can be quantified 7.5 h post-infection using a fluorescence microscope with automated counting analysis software. This approach enabled the development of an eGFP-reduction neutralization test (GRNT) ([Figure 2](#fig2){ref-type="fig"}D).

Neutralization of VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2 by Human Antibodies {#sec2.5}
--------------------------------------------------------------------------

Members of our group recently identified human mAbs from memory B cells of a SARS-CoV survivor that bind to SARS-CoV-2 S ([@bib41]). We tested a subset of these (mAbs 304, 306, 309, and 315) for their ability to inhibit VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2 infections on Vero E6 cells. While three of these mAbs showed poor inhibitory activity, mAb 309 potently neutralized both SARS-CoV-2 and VSV-SARS-CoV-2-S~Δ21~ ([Figures 3](#fig3){ref-type="fig"}A and 3B) with similar EC~50~ values between the two assays (81 and 67 ng/mL for SARS-CoV-2 and VSV-SARS-CoV-2-S~Δ21~, respectively). To broaden the test panel, we evaluated the activity of a panel of mAbs generated as part of a phage display library ([@bib35]) by both FRNT and GRNT. Many of these mAbs exhibited moderate neutralization activities in the EC~50~ range of 100 to 500 ng/mL ([Figures 3](#fig3){ref-type="fig"}C and 3D). Nonetheless, we observed the same neutralization trend between VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2 with highly correlated EC~50~ values (\<2-fold differences).Figure 3Neutralization of VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2 by Human Monoclonal Antibodies and hACE2 Decoy Receptors(A and B) Cross-reactive mAbs isolated from a SARS-CoV survivor were tested for neutralizing activity against SARS-CoV-2 (A) or VSV-SARS-CoV-2-S~Δ21~ (B) (n = 2 and 3, respectively).(C and D) SARS-CoV-2 RBD-specific antibodies obtained from a phage library were tested for their capacity to neutralize SARS-CoV-2 (C) or VSV-SARS-CoV-2-S~Δ21~ (D) (n = 2 and 2, respectively).(E and F) hACE2-Fc or mACE2-Fc were tested for their neutralization activity against SARS-CoV-2 (E) or VSV-SARS-CoV-2-S~Δ21~ (F) (n = 2 and 3, respectively).Error bars in (A)--(F) represent the standard error of the mean. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Neutralization by Human ACE2-Fc Receptor Decoy Proteins {#sec2.6}
-------------------------------------------------------

Human ACE2 (hACE2) is an entry receptor for both SARS-CoV and SARS-CoV-2 ([@bib28]; [@bib29], [@bib30]; [@bib56]). As a soluble hACE2-Fc decoy protein has been proposed as a therapeutic for SARS-CoV-2 ([@bib26]), in part based on its ability to inhibit SARS-CoV infection in cell culture ([@bib36]), we tested whether hACE2-Fc could inhibit infection of VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2 using our FRNT and GRNT assays. When pre-mixed with VSV-SARS-CoV-2-S~Δ21~ or SARS-CoV-2, hACE2-Fc, but not murine ACE2-Fc (mACE2-Fc), it dose dependently and equivalently inhibited infection of recipient Vero E6 cells ([Figures 3](#fig3){ref-type="fig"}E and 3F). As expected, hACE2-Fc did not inhibit infection of wild-type VSV, confirming that neutralization was specific to the SARS-CoV-2 S protein ([Figure S3](#mmc1){ref-type="supplementary-material"}). We noted that a relatively high concentration of hACE2-Fc was required for inhibition, with EC~50~ values of 29 and 12.6 μg/mL for VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2, respectively. Thus, although soluble hACE2-Fc decoy proteins similarly inhibit infection of VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2, the potency is less than anticipated, which suggests that the receptor-binding domain (RBD) on the S protein on the surface of both viruses may not be fully accessible in solution.

Neutralization of VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2 by Human Immune Serum {#sec2.7}
----------------------------------------------------------------------------

As part of studies to evaluate immune convalescent plasma as a possible therapy for SARS-CoV-2-infected patients ([@bib3]), we obtained 42 serum samples from 20 individuals at different time points after the onset of COVID-19 symptoms ([Table 1](#tbl1){ref-type="table"} ). These samples were pre-screened using a commercially available IgG ELISA. We tested each sample for neutralization of VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2 on Vero E6 cells. We observed that sera with ELISA-negative or indeterminate results generally showed low inhibitory titers (EC~50~ \< 1/100), whereas ELISA-positive sera generated a broad range of neutralizing antibody activity (EC~50~ \> 1/200 to \> 1/1,900) ([Figures 4](#fig4){ref-type="fig"} A and [S4](#mmc1){ref-type="supplementary-material"}). Remarkably, neutralization of VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2 was similar across the entire panel of samples ([Figures 4](#fig4){ref-type="fig"}B, 4C, and [S4](#mmc1){ref-type="supplementary-material"}).Table 1Human Serum ELISA IgGSerumDays Post Symptom OnsetEuroimmun IgGEpitope IgGIndexReactiveIndexReactive1141.3+2.6+2126.0+3.5+31710.2+3.9+41614.9+4.5+550.2−1.2+6198.6+4.4+7177.1+4.1+8105.1+2.0+9146.8+3.1+1060.2−1.1+11-5.6+0.9+/−12-\<0.8−1.3+1390.7−1.1+14203.6+2.9+15130.4−2.0+16130.5−0.9−17110.3−0.8−18100.2−0.7−19140.9+/−1.2+20100.4−1.5+21110.5−2.0+22100.3−0.6−23177.6+4.2+24143.5+3.3+25131.5+2.9+261714.2+4.4+27130.5−1.9+28149.2+4.6+29133.9+2.8+30163.4+4.6+311510.7+3.6+3260.5−1.1+33110.4−1.8+34120.6−2.5+35143.7+4.1+362011.6+4.2+3770.7−1.2+3881.7+1.9+3970.3−0.7−4093.4+2.2+411810.3+4.1+421710.3+4.6+[^3]Figure 4Human Immune Serum Neutralization of SARS-CoV-2 and VSV-SARS-CoV-2-S~Δ21~(A and B) Representative neutralization curves of serum from SARS-CoV-2-infected donors with low, medium, and high inhibitory activity against SARS-CoV-2 (A) or VSV-SARS-CoV-2-S~Δ21~ (B) (n = 2 and 2, respectively). Error bars in (A) and (B) represent the standard error of the mean.(C) EC~50~ values of all human serum tested for neutralization of SARS-CoV-2 and VSV-SARS-CoV-2-S~Δ21.~ Differences in the geometric mean or median titers were 3.0-fold between FRNT and GRNT assays. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2 Neutralization Assays Are Highly Correlative {#sec2.8}
---------------------------------------------------------------------------------

We determined the extent to which the VSV-SARS-CoV-2-S~Δ21~ and SARS-CoV-2 neutralization tests correlated with each other. We compared the GRNT and FRNT EC~50~ values obtained in assays with mAbs, polyclonal sera, and soluble ACE2 protein ([Figure 5](#fig5){ref-type="fig"} ). For the samples with neutralizing activity, we observed a remarkably strong correlation between the two assays (*r* = 0.9285; p \< 0.001). Moreover, all 11 of the samples that were deemed non-neutralizing in one assay had the same result in the second assay. Together, these results establish the utility of using VSV-SARS-CoV-2-S~Δ21~ as a surrogate for authentic SARS-CoV-2 infection in entry inhibition and neutralization studies.Figure 5Correlation Analysis of Neutralization of SARS-CoV-2 and VSV-SARS-CoV-2-S~Δ21~EC~50~ values determined in [Figures 3](#fig3){ref-type="fig"}A--3D and [4](#fig4){ref-type="fig"}A--4B were used to determine correlation between neutralization assays. Spearman's correlation *r* and *p* values are indicated.

Discussion {#sec3}
==========

Emerging viral pathogens have caused numerous epidemics and several pandemics over the last century. The most recent example, SARS-CoV-2, has spread to nearly every country in the world in just a few months, causing millions of infections and hundreds of thousands of deaths (<https://www.worldometers.info/coronavirus/>). Rapid responses to viral outbreaks and generation of countermeasures require readily accessible tools to facilitate study and evaluate antiviral activity. Here, we generated a high-titer, replication-competent chimeric VSV expressing the SARS-CoV-2 S protein that performs similarly to a SARS-CoV-2 clinical isolate across multiple neutralization tests. As access to BSL3 facilities is limited, the finding that VSV-SARS-CoV-2-S~Δ21~ is neutralized similarly by decoy receptors, mAbs, and polyclonal antibodies in comparison to authentic SARS-CoV-2 is important. This tool will enable academic, government, and industry investigators to rapidly perform assays that interrogate SARS-CoV-2 entry, neutralization, and inhibition at a BSL2 level, which should simplify and expedite the discovery of therapeutic interventions and analysis of functional humoral immune responses.

Upon recovery of VSV-SARS-CoV-2-S~AA~, we selected for a mutant, which contained a 21-amino acid deletion in the cytoplasmic tail. As truncation of the cytoplasmic tail eliminates the modified KxHxx ER retention signal, we suggest that this mutation facilitates more efficient incorporation of the SARS-CoV-2 S protein into the VSV particles. Although truncation of the cytoplasmic tail of HIV envelope protein resulted in conformational alterations in the ectodomain of the protein ([@bib9]), based on the extensive neutralization data presented here, including correlation to neutralization of a clinical isolate of SARS CoV-2, a 21-amino acid truncation does not appear to substantively alter the structure of the S protein ectodomain. It remains to be determined whether fully wild-type S protein can incorporate efficiently into VSV. Indeed, similar mutations were generated in the SARS-CoV S protein cytoplasmic tail to boost incorporation into retroviruses and VSV pseudotypes ([@bib15]; [@bib20]; [@bib36]).

The value of a chimeric virus depends on its capacity to present viral surface antigens in a similar way to its authentic counterpart ([@bib18]). Indeed, the morphology of the bullet-shaped rhabdovirus and the spherical coronavirus and the density and geometry of S protein display could differentially impact antibody engagement and neutralization. Despite this concern, our extensive testing of VSV-SARS-CoV-2-S~Δ21~ with antibodies and soluble ACE2-Fc proteins showed similar neutralization profiles compared to authentic, fully infectious SARS-CoV-2. Thus, VSV-SARS-CoV-2-S~Δ21~, despite the structural differences of the virion, provides a useful tool for screening antibodies, entry-based antiviral agents, and vaccine responses against SARS-CoV-2. Indeed, convalescent plasma is under investigation as a potential COVID-19 therapeutic ([@bib11]). Our studies suggest that, in addition to testing for anti-S or anti-RBD antibodies ([@bib44]), neutralization assays with VSV-SARS-CoV-2-S~Δ21~ may be a convenient and rapid method to obtain functional information about immune plasma preparations to enable prioritization prior to passive transfer to COVID-19 patients.

Coronaviruses possess a roughly 30 kb RNA genome, which requires that they encode a proofreading enzyme (ExoN in nsp14) ([@bib13]) to counteract the error rate of the viral-RNA-dependent RNA polymerase. The lack of such proofreading enzymes in the genomes of rhabdoviruses suggests that selection of escape mutants to inhibitors of the coronavirus S protein will be faster in VSV-SARS-CoV-2, which further increases the utility of this chimeric virus. Our FRNT and GRNT assays can be used to establish evidence of prior SARS-CoV-2 infection or vaccination, as well as determine waning of functional responses over time, as the likelihood of cross-neutralizing responses with other cosmopolitan coronaviruses (*e.g*., HCoV-229E and HCoV-OC43) is exceedingly low. Overall, VSV-SARS-CoV-2-S~Δ21~ and our FRNT and GRNT assays can facilitate the development and evaluation of antibody- or entry-based countermeasures against SARS-CoV-2 infection. A similar VSV-SARS-CoV-2 chimera as a reporter of antibody mediated neutralization is described in a companion paper ([@bib61]).

Limitations of Study {#sec3.1}
--------------------

Our experiments do not directly test the safety of the recombinant VSV-eGFP-SARS-CoV-2. VSV-Indiana and chimeric VSV in which the native envelope protein is replaced with that of the envelope proteins of Ebola ([@bib18]; [@bib24]; [@bib47]), Lassa ([@bib19]), Andes ([@bib4]), highly pathogenic avian influenza ([@bib17]), and many other viruses are handled at BSL2. VSV-Ebola is a licensed human vaccine, ERVEBO, distributed by Merck. We are actively evaluating VSV-SARS-CoV-2 as a vaccine candidate, and mice inoculated with this virus do not develop disease (J.B.C., P.W.R., S.P.J.W., and M.S.D., unpublished data). Notwithstanding these data, a chimeric VSV containing both the F and G genes of Nipah virus remains pathogenic in mice ([@bib52]), suggesting that appropriate caution should be used in handling VSV-SARS-CoV-2 at BSL2.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------
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Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact author Sean P.J. Whelan (<spjwhelan@wustl.edu>).

### Materials Availability {#sec4.2.2}

All plasmids, antibodies, cells, viruses, and cell lines developed are available under Material Transfer Agreements from Washington University School of Medicine.

### Data and Code Availability {#sec4.2.3}

The authors declare that all data supporting the findings of this study are available within the paper. The sequence of VSV-eGFP-SARS-CoV-2-S~Δ21~ (passage 12) generated during this study is available through NCBI (SRA: SRR11878607, <https://www.ncbi.nlm.nih.gov/sra/?term=SRR11878607>; BioProject: PRJNA635934).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cells {#sec4.3.1}

Cells were maintained in humidified incubators at 34 or 37°C and 5% CO~2~ in the indicated media. BSRT7/5, Vero CCL81, Vero E6, Vero E6-TMPRSS2, A549, Caco-2, Caco-2 BBe1, Calu-3, Huh7.5.1, HepG2, H1Hela, BHK-21, HEK293, and HEK293T were maintained in DMEM (Corning or VWR) supplemented with glucose, L-glutamine, sodium pyruvate, and 10% fetal bovine serum (FBS). Vero-furin cells ([@bib37]) also were supplemented with 5 μg/mL of Blasticidin S HCl (GIBCO). MA104 cells were maintained in Medium 199 (GIBCO) containing 10% FBS. HT-29 cells were cultured in complete DMEM/F12 (Thermo Fisher) supplemented with sodium pyruvate, non-essential amino acids, and HEPES (Millipore Sigma). Vero E6-TMPRSS2 cells were generated using a lentivirus vector. Briefly, HEK293T producer cells were transfected with pLX304-TMPRSS2, pCAGGS-VSV-G, and psPAX2, and cell culture supernatants were collected at 48 h and clarified by centrifugation at 1,000 x g for 5 min. The resulting lentivirus was used to infect Vero E6 cells for 24 h, and cells were selected with 40 μg/mL Blasticidin S HCl for 7 days.

### Recombinant VSV {#sec4.3.2}

Recovery of recombinant VSV was performed as described ([@bib55]). Briefly, BSRT7/5 cells ([@bib5]) were inoculated with vaccinia virus vTF7-3 ([@bib14]) and subsequently transfected with T7-expression plasmids encoding VSV N, P, L, and G, and an antigenomic copy of the viral genome. Cell culture supernatants were collected at 56-72 h, clarified by centrifugation (5 min at 1,000 x g), and filtered through a 0.22 μm filter. Virus was plaque-purified on Vero CCL81 cells in the presence of 25 μg/mL of cytosine arabinoside (Sigma-Aldrich), and plaques in agarose plugs were amplified on Vero CCL81 cells. Viral stocks were amplified on MA104 cells at an MOI of 0.01 in Medium 199 containing 2% FBS and 20 mM HEPES pH 7.7 at 34°C. Viral supernatants were harvested upon extensive cytopathic effect and clarified of cell debris by centrifugation at 1,000 x g for 5 min. Aliquots were maintained at −80°C. Construction and use of VSV-SARS-CoV-2 was approved by the Washington University School of Medicine Institutional Biosafety Committee at Biosafety level 2.

### SARS-CoV-2 {#sec4.3.3}

SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 was obtained from the Centers for Disease Control and Prevention (gift of Natalie Thornburg). Virus was passaged in the indicated producer cells ([Figures 2](#fig2){ref-type="fig"}A--2C). Work with SARS-CoV-2 was approved by the Washington University School of Medicine Institutional Biosafety Committee at Biosafety level 3 with positive pressure respirators.

Method Details {#sec4.4}
--------------

### Plasmids {#sec4.4.1}

The S gene of SARS-CoV-2 isolate Wuhan-Hu-1 (GenBank MN908947.3) was synthesized in two fragments (Integrated DNA Technologies) and inserted into an infectious molecular clone of VSV ([@bib8]; [@bib55]) as previously ([@bib7]; [@bib23]). Modifications to the cytoplasmic tail were assembled identically, and accession numbers or references to the amino acid sequences used for the MERS and VSV G tail mutants can be found in the [Key Resources Table](#sec4.1){ref-type="sec"}. Other plasmids were previously described: VSV N, P, L and G expression plasmids ([@bib45]; [@bib55]), psPAX2 (Addgene), and pLX304-TMPRSS2 ([@bib58]).

### Next Generation Sequencing {#sec4.4.2}

Total RNA was extracted from Vero CCL81 cells infected with VSV-SARS-CoV-2-S~Δ21~ using TRIzol (Invitrogen) according to the manufacturer's protocol. RNA was used to generate next generation sequencing libraries using TruSeq Stranded Total RNA library kit with Ribo Zero ribosomal subtraction (Illumina). The libraries were quantified using a bioanalyzer (Agilent) and pooled at an equal molar concentration and used to generate paired end 250 bp reads on a MiSeq (Illumina). Raw sequencing data was processed using fastp v0.20.0 ([@bib10]) to cut adaptor sequences and filter out sequences with a Phred quality score \< 30. Processed reads were aligned to the reference plasmid sequence using BBMap v38.79 ([@bib6]). Reads that mapped to the reference were extracted using SAMtools 1.9 ([@bib32]). The extracted mapped reads were used as input for *de novo* assembly with SPAdes v3.13.0 ([@bib2]). Assembled contigs produced a 14.2 kb consensus sequence, which was subsequently aligned to the reference plasmid using NUCmer v3.1 ([@bib12]). Consensus sequences for each RNA sample were generated by aligning contigs to the reference plasmid sequence pVSV(1+)-eGFP-SARS-CoV-2-S with SnapGene v5.0.

### Western Blotting {#sec4.4.3}

Purified VSV virions were incubated in non-reducing denaturation buffer (55 mM Tris-HCl pH 6.8, 1.67% (w/v) SDS, 7.5% (w/v) glycerol) at 100°C for 5 min. Viral proteins were separated on a 8% acrylamide gel, transferred onto a nitrocellulose membrane, and incubated with human anti-SARS antibody CR3022 diluted in Tris-buffered saline containing 1% Tween-20 (TBS-T) and 5% milk, followed by incubation with HRP-conjugated goat anti-human antibody (Abcam) diluted in TBS-T containing 1% milk. HRP activity was visualized using the Pierce ECL western blotting kit (Thermo Scientific) and imaged with a ChemiDocTM MP Imager (Bio-Rad).

### Metabolic Radiolabeling of Virions {#sec4.4.4}

To generate high titer stocks of VSV-SARS-CoV-2, BSRT7/5 cells were transfected with pCAGGS-VSV-G in Opti-MEM (GIBCO) using Lipofectamine 2000 (Invitrogen) and infected 7 h later with VSV-SARS-CoV-2-S~Δ21~ at an MOI of 0.1 in DMEM containing 2% FBS and 20 mM HEPES pH 7.7. Viral stocks were collected at 48 hpi, and used to infect fresh cells (MOI of 10) for labeling of viral proteins. At 4 hpi, cells were starved in serum free, methionine/cysteine free DMEM (Corning), and exposed to 15 μCi/mL \[^35^S\]-methionine and \[^35^S\]-cysteine (Perkin Elmer) from 5-24 h in the presence of actinomycin D. Cell culture supernatants were collected, clarified by centrifugation (1,500 x g, 5 min), and analyzed by SDS-PAGE and detected by phosphoimage analysis ([@bib31]).

### Transmission Electron Microscopy {#sec4.4.5}

Purified viruses were adhered to glow-discharged, carbon-coated copper grids. Samples were stained with 2% (w/v) phosphotungstic acid (Sigma-Aldrich), pH 7.1, in H~2~O and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc.) equipped with an AMT 8-megapixel digital camera and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques).

### Monoclonal Antibodies {#sec4.4.6}

Phage-displayed Fab libraries were panned against immobilized SARS-CoV-2 spike RBD in multiple rounds using established methods ([@bib40]). Following four rounds of selection, phage ELISAs were used to screen 384 clones to identify those that bound specifically to RBD. The complementarity determining regions of Fab-phage clones were decoded by sequencing the variable regions and cloning them into mammalian expression vectors for expression and purification of human IgG1 proteins, as described ([@bib48]). A subset of the panel of mAbs was tested for neutralization as a part of this study.

Another set of mAbs (S304, S306, S309, S310 and S315) were isolated from EBV-immortalized memory B cells from a SARS-CoV survivor ([@bib51]) and are cross-reactive to SARS-CoV-2 ([@bib41]). Recombinant antibodies were expressed in ExpiCHO cells transiently co-transfected with plasmids expressing the heavy and light chain as previously described ([@bib46]).

### Human Sera {#sec4.4.7}

Human samples were collected from PCR-confirmed COVID-19 patients. Serum samples were obtained by routine phlebotomy at different days post symptom onset (range: day 5 - 20). Samples were prescreened by the Euroimmun anti-SARS-CoV-2 IgG ELISA (Lubeck, Germany), a qualitative assay with the Food and Drug Administration Emergency Use Authorization that detects antibodies to the SARS-CoV-2 S protein. This study was approved by the Mayo Clinic Institutional Review Board.

### Protein Expression and Purification {#sec4.4.8}

DNA fragments encoding human ACE2 (hACE2 residues 1-615) and mouse ACE2 (mACE2, residues 1-615) were synthesized and cloned into pFM1.2 with a C-terminal HRV-3C protease cleavage site (LEVLFQGP) and a human IgG1 Fc region as previously described ([@bib42]). We transiently transfected plasmids into Expi293F cells and harvested cell supernatants 4 days post transfection. Secreted hACE2-Fc and mACE2-Fc proteins were purified by protein A chromatography (GoldBio).

### GFP-Reduction Neutralization Test {#sec4.4.9}

Patient samples were heat-inactivated at 56°C for 30 min. Indicated dilutions of samples were incubated with 10^2^ PFU of VSV-SARS-CoV-2-S~Δ21~ for 1 h at 37°C. Antibody-virus complexes were added to Vero E6 cells in 96-well plates and incubated at 37°C for 7.5 h. Cells subsequently were fixed in 2% formaldehyde (Millipore Sigma) containing 10 μg/mL Hoechst 33342 nuclear stain (Invitrogen) for 45 min at room temperature, when fixative was replaced with PBS. Images were acquired with the InCell 2000 Analyzer (GE Healthcare) automated microscope in both the DAPI and FITC channels to visualize nuclei and infected cells (*i.e*., eGFP-positive cells), respectively (4X objective, 4 fields per well, covering the entire well). Images were analyzed using the Multi Target Analysis Module of the InCell Analyzer 1000 Workstation Software (GE Healthcare). GFP-positive cells were identified in the FITC channel using the top-hat segmentation method and subsequently counted within the InCell Workstation software. The sensitivity and accuracy of GFP-positive cell number determinations were validated using a serial dilution of virus. A background number of GFP+ cells was subtracted from each well using an average value determined from at least 4 uninfected wells. Data were processed using Prism software (GraphPad Prism 8.0). ACE2 neutralization assays using VSV-SARS-CoV-2-S~Δ21~ were conducted similarly but using an MOI of 1. Infection and imaging of Calu-3 cells was performed using similar methods, though cells were infected at an MA104-calculated MOI of 20. Cells were imaged using a 10X objective, with 9 fields per well. FITC and DAPI fields were overlaid using ImageJ and contrast-adjusted identically.

### Focus-Reduction Neutralization Test {#sec4.4.10}

Indicated dilutions of mAbs, sera, or protein were incubated with 10^2^ FFU of SARS-CoV-2 for 1 h at 37°C. Antibody-virus complexes were added to indicated cell monolayers in 96-well plates and incubated at 37°C for 1 h. Subsequently, cells were overlaid with 1% (w/v) methylcellulose in MEM supplemented with 2% FBS. Plates were harvested 30 h later by removing overlays and fixed with 4% paraformaldehyde in PBS for 20 min at room temperature. Plates were washed and sequentially incubated with 1 μg/mL of CR3022 anti-S antibody ([@bib49]; [@bib57]) and HRP-conjugated goat anti-human IgG in PBS supplemented with 0.1% saponin and 0.1% BSA. SARS-CoV-2-infected cell foci were visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot microanalyzer (Cellular Technologies). Data were processed using Prism software (GraphPad Prism 8.0).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

All statistical tests were performed using GraphPad Prism 8.0 software as described in the indicated figure legends. Statistical significance was assigned when P values were \< 0.05. The number of independent experiments and the statistical tests used are indicated in the relevant Figure legends. Error bars indicate standard error of the mean unless stated otherwise.
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